In patients with advanced melanoma, approximately one-half harbor a mutation in the BRAF gene, and they experience significant long-term treatment benefit from targeted therapy with BRAF or MEK (mitogen-activated protein kinase) inhibitors. This evidence concerns the gene BRAF and melanoma.